Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer’s Troxyca ER Opioid Combo Faces Intravenous Abuse Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

More oxycodone was extracted from the combination product, potentially defeating the opioid-blunting effects of the naltrexone component and creating a hurdle to an abuse-deterrent claim.

Advertisement

Related Content

Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register